Objective: Glutamate and GABA are the key neurotransmitter systems in the cortico-thalamocortical network, involved in normal and pathological oscillations such as spike-wave discharges (SWDs) characterizing different forms of absence epilepsy. Metabotropic glutamate (mGlu) and GABA receptors are widely expressed within this network. Here, we examined the effects of two selective positive allosteric modulators (PAMs) of mGlu1 and mGlu5 receptors, the GABA reuptake inhibitor, tiagabine, and their interaction in the somatosensory cortex and thalamus on SWDs in WAG/Rij rats.
INTRODUCTION

3
Dysfunction in either glutamatergic or GABAergic neurotrasmission is known to be one of the causes responsible for the initiation and spread of seizures, including absence epilepsy. Known as the electroencephalographic hallmark of absence seizures, the archetypical spike-wave discharges (SWDs) are initiated in the deep layers of the somatosensory cortex and quickly spread to the cortico-thalamo-cortical (C-T-C) network. 1, 2 This network consists of glutamatergic projections from the deep layer cortical neurons to ventrobasal (VB) thalamic nuclei including the S1po, and to the reticular thalamic nucleus (nRT); glutamatergic projections from VB thalamic nuclei to the cortex and nRT; and GABAergic projection from the nRT to VB thalami nuclei. 2, 3 Several mGlu receptor subtypes appear strategically distributed at the synapses of the C-T-C loop. In the cortex, group-I mGlu receptors (namely mGlu1 and mGlu5 receptors) are expressed post-synaptically on GABAergic interneurons. 4, 5, 6 At thalamic level, group I mGlu receptors are present post-synaptically on glutamatergic neurons of the VB complex reviewed by Ngomba et al., 2011. 7 These neurons express moderate levels of mGlu5 receptor immunoreactivity, 8 while the mGlu1 receptors mainly reside in the perisynaptic area. 9, 10, 11, 12 Modulatory effects of individual mGlu receptor subtypes on both excitatory and inhibitory synaptic transmissions in the C-T-C circuit have been found, and subtype-selective mGlu receptor ligands were proposed as potential candidates for novel antiabsence drugs. 7 Studies with mGlu receptor ligands have been conducted in WAG/Rij rats, which develop spontaneous absence seizures after 2-3 months of age. 7 Systemic administration of compounds RO0711401 and VU0360172, which behave as selective positive allosteric modulators (PAMs) of mGlu1 and mGlu5 receptors, respectively, decrease the incidence of SWDs in symptomatic WAG/Rij rats. 13, 14 No tolerance develops to the anti-absence activity of VU0360172, whereas the activity of RO0711401 declines after the first three days of repeated administrations. 15 Where precisely within the C-T-C circuit activation of mGlu1 or mGlu5 receptors reduces SWDs is unknown. Here, we have addressed this question by locally injecting either VU0360172 or RO0711401 in the VB part of the thalamus or in the somatosensory cortex.
Next to the role of glutamate, GABA also holds a key position in the control of SWDs. It is well known that systemically administered GABA-mimetics, such as tiagabine, acting by blocking the reuptake of GABA via the high affinity GABA transporter, GAT-1, 16 aggravate the 4 incidence of SWDs. 17 Here, we also investigated whether GABAergic regulation of absence seizures differs in the thalamus and cerebral cortex. WAG/Rij rats represent an appropriate model to examine this issue because in these rats as well as in GAERS (genetic absence epileptic rats of Strasbourg, 18 a high excitability of S1po is a prerequisite for the initiation of SWDs 1, 2 that are then sustained by an enhanced tonic GABAergic inhibition in the thalamus. 19, 20 Finally, using tiagabine, we examined whether, and in which direction, an increased availability of (extra)synaptic GABA influences responses to the mGlu5 receptor PAM, VU0360172, in the thalamus and somatosensory cortex.
Materials and Methods
Animals
One hundred and thirty one male WAG/Rij rats were used for all experiments. Of these, eight animals were excluded because of a wrong position of the cannulas either in the cortex or in the thalamus. All rats were born and raised at Radboud University Nijmegen, The Netherlands, and had a mean body weight of about 350 g at 9 months of age. Rats of this age have about [16] [17] [18] [19] [20] SWDs per hour, adding several hundred SWDs per day. 21 The animals were housed in pairs in
Macrolon cages, kept under controlled conditions (20ºC, 60% humidity) in a room with a reversed light-dark cycle (white light on from 9 p.m. to 9 a.m.), with food and drinking water always available. After surgery, rats were kept individually. Animals were handled regularly before starting EEG registrations to reduce handling stress imposed by the local injections. The study was performed in accordance with the guidelines of the European Community for the use of experimental animals and was approved by local ethics committee for animal studies (RU-DEC). All efforts were made to reduce discomfort experienced by the animals and to keep the number of animals as low as possible. In all 3 experiments (Table 1) , bilateral microinfusions in the peri-oral region of the somatosensory cortex (S1po) or in the VB thalamic nuclei were performed using artificial cerebro spinal fluid (ACSF) as vehicle. Drugs were soluble in ACSF at concentrations of 1 mg/ml (VU0360172, RO0711401) or 2 mg/ml (tiagabine). In experiments with single injections, drugs were always microinfused in a volume of 1 µl. Doses were 1 µg for VU0360172 and RO0711401, and 0.5, 1 or 2 µg for tiagabine. In experiments in which VU0360172 and tiagabine were co-administered, the two drugs were infused with a 3 min interval. In the S1po, both VU0360172 and tiagabine were infused at doses of 1 µg in a volume of 1 µl (i.e., 1 µl + 1 µl with 3 min of interval). In the thalamus, VU0360172 was infused at the dose of 1 µg whereas tiagabine was infused at the dose of 0.5 µg (always in a volume of 1 µl). ACSF was infused twice with 3 min interval in control animals. Infusions were performed by means of a Hamilton syringe at a flow rate of 1 µl per min and the injection needle remained in the cannula after each single injection for 2 min to prevent backflow. The needle necessary for doing local injections did not protrude from the guide cannulas in order to avoid a spreading depression induced by the local injection. 23 In all experiments, cortical EEG was recorded and motor behavior was quantified as detailed in the Supporting Information. Surgical procedures, coordinates used for the implantation of guide cannulas, and the procedure we have used to determine the position of the guide cannulas are described in detail in the Supporting Information. 6 The effects of intracortical or intrathalamic drug injections on the incidence and mean duration of SWDs, and locomotor activity were tested in separate repeated-measures ANOVAs with incidence and mean duration of SWDs or amplitude of the PIR as dependent variables. The hourly incidence (number) and mean of SWDs in the 2 hours before injection were determined and differences between groups were analyses with a simple one-factor ANOVA (groups) for all three experiments. For all post-injection analyses, the time of EEG recording (6x10 minutes blocks post injection) was used as the within subjects factor, group (either site of injection of different drugs) was used as between subjects factor. In Experiment 2 and 3 repeated measures were conducted as well, but now different doses of tiagabine in cortex and thalamus (Experiment 2), or the different groups (Experiment 3 co-injection group, ACSF + ACSF), were used as between subjects factors, all followed by post-hoc tests, if appropriate. One way ANOVAs and
Drugs and experimental protocol
Statistical analysis
Duncan post-hoc tests were used to isolate differences between the locations, doses or different drug treated groups at the different 10 minute episodes. Results are expressed as mean ± SEM and calculations were obtained using SPSS 19 software. The level of statistical significance was set at p < .05. None of the treatments caused significant differences in the mean duration of SWDs (Fig. 1D,E) and in locomotor activity (Fig. 1F,G) . Tiagabine was injected at doses of 1 or 2 µg in the S1po (n = 8 in both groups), and 0.5, 1, or 2 µg in the VB thalamus (n = 4, 5, and 5, respectively). Control rats received ACSF (n = 8 in both S1po and thalamus). There were no differences between the groups before drug administration.
Results
Effects of microinfusion of VU0360172, RO0711401 or ACSF in the
Intracortical injection of tiagabine reduced the incidence of absence seizures. Two-way ANOVA Treatment with tiagabine did neither change the mean duration of SWDs (Fig. 2C,D) nor locomotor activity scores (Fig. 2E,F) .
Effects of combined injections of VU0360172 and tiagabine in the cortex and thalamus
In all experiments, injection of VU0360172 (1 µg in both S1po and VB thalamus) preceded by 3 min the injection of tiagabine (1 µg in the S1po, and 0.5 µg in the VB thalamus; n = 8 and 9, respectively). Control rats received two sequential injections of ACSF in the S1po or in the VB thalamus (n = 8 and 9, respectively). There were no differences between the groups before drug administration. Data obtained after intracortical injections are shown in Fig. 3A . Two-way ANOVA for repeated measures after injections of VU0360172 + tiagabine and ACSF + ACSF None of these treatments had any effect on the mean duration of SWDs (Fig. 3C,D ) and locomotor activity (Fig. 3E,F ).
Discussion
Our experiments were a follow-up from the evidence that systemic administration of group-I mGlu receptor PAMs reduces the incidence of SWDs in WAG/Rij rats. 7, 13, 14 Here, we showed that this effect could be induced by injecting mGlu1 or mGlu5 receptor PAMs in both the S1po and ventrobasal thalamic nuclei. There was a difference in the thalamic and cortical response to RO0711401 and VU0360172. The two drugs were equally effective in reducing SWDs when injected in the cortex; in contrast, the mGlu5 PAM, VU036012, displayed a greater efficacy than the mGlu1 PAM, RO0711401, when injected in the thalamus. The somatosensory cortex is the main site of origin of SWDs in WAG/Rij and GAERS rats, 1 and this region is highly excitable. channel-dependent fashion, resulting in absence epilepsy. 26 Thus, activation of either mGlu1 or mGlu5 receptors present in VB thalamic neurons might restrain the occurrence of absence seizures by negatively regulating the activity of T-type Ca 2+ channels on thalamo-cortical cells.
However, intrathalamic injection of VU036172 caused a more robust and prolonged suppression of SWDs as compared to intrathalamic injection of RO0711401, suggesting that an additional mechanism that is peculiar to mGlu5 receptors contributes to restrain the occurrence of SWDs. A major difference between mGlu1 and mGlu5 receptors is that only the latter are found on astrocytes, both in the thalamus and cerebral cortex. 27, 28 Astrocytes are key players in the regulation of thalamic oscillations because they clear extracellular glutamate and GABA, thereby limiting the activation of extrasynaptic glutamate and GABA receptors.
An increased inhibitory GABAergic transmission at the synapses between reticular thalamic neurons and VB thalamic neurons sustains the occurrence of SWDs (reviewed by Blumenfeld,
2005)
2 , and this explains the pro-absence effect seen after systemic administration of drugs that enhance GABAergic transmission, such as tiagabine, vigabatrin, and the neurosteroid allopregnanolone in both GAERS and WAG/Rij rats. 16, 29, 18, 30 Intrathalamic injections of the GABA-transaminase inhibitor, γ-vinyl GABA, the GABA A receptor agonist, muscimol, or the neurosteroids, allopregnanolone or ganaxolone also increase the incidence of SWDs. 31, 32 Tiagabine enhances tonic inhibition of thalamic relay neurons by inhibiting GABA re-uptake, and, therefore, facilitating the endogenous activation of extrasynaptic GABA receptors. 33, 19, 34 Hence, the enhanced incidence of SWDs found after intrathalamic injection of tiagabine was fully expected and suggests that the pro-absence activity in the thalamus prevails over the antiabsence activity in the cortex after systemic injection of tiagabine.
Experiments in which the mGlu5 receptor PAM, VU036172 was co-injected with sub-threshold doses of tiagabine in the VB thalamus produced interesting results. If combined with tiagabine, VU036172 was still effective in reducing the incidence of SWDs in the early post-injection time (10 min), but then lost this effect at 20 min, and displayed a paradoxical pro-absence effect at 30 and 40 min. This suggests that the regulation of thalamic oscillations by mGlu5 receptors is shaped by extracellular GABA, or, alternatively, that the mGlu5 receptor controls the activity of the GABA transporter, GAT-1, in astrocytes or in GABAergic fibers afferent to VB thalamic nuclei. Activation of glial mGlu5 receptors is known to regulate the expression of the glial glutamate transporters, GLT-1 and GLAST. 35 If this regulation extends to GAT-1, and we may suggest the following scenario. Pharmacological enhancement of mGlu5 receptors produces pleiotropic effects in the VB thalamus, including an enhanced clearance of extracellular GABA, which might be critical for the suppression of SWDs. In the presence of a GAT-1 inhibitor (e.g., tiagabine) activation of mGlu5 receptors will not stimulate GABA reuptake, and the progressive increase in extracellular GABA will block the anti-absence action mediated by mGlu5 receptor stimulation. Studies on GABA uptake in cultured astrocytes or studies on tonic inhibition in thalamic slices in epileptic and non-epileptic rats are needed to verify this hypothesis.
In conclusion, group I metabotropic receptors are involved in the control of absence seizures through the entire C-T-C network that is responsible for the pathological oscillations associated In the S1po cortex, pharmacological enhancement of mGlu1 or mGlu5 receptors might reduce absence seizures by activating somatostatin (SST)-positive GABAergic interneurons, and tiagabine might produce the same effect by enhancing GABA levels at the synapses between between SST + interneurons and pyramidal neurons.
In the ventrobasal thalamus, tiagabine enhances absence seizures by increasing synaptic and extrasynaptic GABA levels, thereby facilitating the activity of T-type voltage-sensitive Ca 2+ channels. mGlu1 and mGlu5 receptors might protect against absence seizures by directing modulating T-type Ca 2+ channels (modulation of T-type channels by phospholipase C has been reported 26 ) or through a blockade of the glial glutamate transporter 35 . Tiagabine might act via blockade of the presynaptic and glial GABA transporter.
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Data on the interaction between VU0360172 and tiagabine raise the possibility that mGlu5 receptors regulate the expression or activity of GAT-1 in GABAergic terminals and/or astrocytes. 1 µg + 1 µg (n=8) S1Po VU0360172 + followed by tiagabine (3 min interval)
1 µg + 0.5 µg (n=9) VB ACSF followed by ACSF (3 min interval)
ACSF followed by ACSF (3 min interval) (n=8) (n=9) S1Po VB
